From: PR status is a more decisive factor in efficacy of adding pertuzumab into neoadjuvant therapy for HER2-positive and lymph node-positive breast cancer than ER status: a real-world retrospective study in China
PR status
ER status
Group H
N (%)
Group HP
PR-positive
ER-positive
7 (25.00)
4 (25.00)
ER-negative
1 (33.33)
3 (37.50)
PR-negative
5 (27.78)
4 (80.00)
12 (31.58)
21 (80.77)
Total
25 (28.7)
32 (58.2%)